We reported a case of a 65-year-old male who had been treated with obinutuzumab and chemotherapy for follicular lymphoma. He was infected with SARS-CoV-2 after the second course of therapy. He developed fever, cough and bilateral pulmonary infiltrates. His nasopharyngeal swab became negative only temporarily after repeated courses of antiviral therapy, and the symptoms and pulmonary infiltrates waxed and waned. He presented to our hospital with exertional dyspnea and hypoxemia after his nasopharyngeal swab was positive for SARS-CoV-2 for the fourth time. He had an elevated serum lactate dehydrogenase and a positive 1, 3-β-D-glucan test. The PCR test for Pneumocystis jirovecii in the sputum was positive. The patient was diagnosed with persistent COVID-19 and Pneumocystis jirovecii pneumonia. He responded well to the combination treatment of antiviral medication, convalescent plasma, trimethoprim-sulfamethoxazole and corticosteroids.
本文报道1例65岁男性患者，因滤泡性淋巴瘤接受奥妥珠单抗治疗联合化疗，于第2程化疗后感染新型冠状病毒，主要表现为发热、咳嗽，影像学示双肺多发磨玻璃影，抗病毒治疗后鼻咽拭子新型冠状病毒核酸可暂时转阴，但此后反复阳性。第4次新型冠状病毒核酸阳性后出现活动后气短，伴低氧血症，乳酸脱氢酶及1，3-β-D葡聚糖试验升高，痰肺孢子菌核酸阳性。诊断新型冠状病毒持续感染、新型冠状病毒肺炎（重型），合并肺孢子菌肺炎，给予康复期血浆输注、磺胺、糖皮质激素治疗后病情好转，出院后随访患者病情稳定。.